Verrica Pharmaceuticals
VRCA
40 hedge funds and large institutions have $68.8M invested in Verrica Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 19 increasing their positions, 8 reducing their positions, and 8 closing their positions.
138% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 8
0.08% more ownership
Funds ownership: 3.21% → 3.29% (+0.08%)
11% less funds holding
Funds holding: 45 → 40 (-5)
49% less capital invested
Capital invested by funds: $134M → $68.8M (-$65.1M)
50% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.37M |
| 2 |
KCM
Kornitzer Capital Management
Shawnee Mission,
Kansas
|
+$1.36M |
| 3 |
GGHC
Gilder Gagnon Howe & Co
New York
|
+$800K |
| 4 |
PVI
Pura Vida Investments
New York
|
+$533K |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$486K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity International
Hamilton,
Bermuda
|
-$2.94M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$839K |
| 3 |
PCM
Prelude Capital Management
New York
|
-$566K |
| 4 |
LCM
Laurion Capital Management
New York
|
-$325K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$287K |
VRCA Hedge Fund Activity: Q4 2018 in Review
40 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Verrica Pharmaceuticals (VRCA) for Q4 2018, worth a combined $68.8M — down 49% from $134M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of VRCA and 4 opened new positions — a net loss of 4 holders — while 8 trimmed existing stakes and 19 added.
The largest buyer was Vanguard Group, adding an estimated $1.37M. The largest seller was Fidelity International, exiting entirely with an estimated $2.94M sold.
- 40 institutional investors held Verrica Pharmaceuticals (VRCA) as of Q4 2018, down from 45 in Q3 2018.
- Funds reported $68.8M of Verrica Pharmaceuticals stock for Q4 2018, down 49% quarter-over-quarter.
- 4 funds opened new Verrica Pharmaceuticals positions in Q4 2018 and 8 closed out, a net change of -4 holders.
- The largest Verrica Pharmaceuticals buyer in Q4 2018 was Vanguard Group, an estimated $1.37M added.
- The largest Verrica Pharmaceuticals seller in Q4 2018 was Fidelity International, an estimated $2.94M sold.
Based on aggregated 13F filings for Q4 2018.